- Association between IPTA Gene Polymorphisms and Hematological Abnormalities in Hepatitis C Virus-Infected Patients Receiving Combination Therapy
-
Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH
- KMID: 2380767
- Gut Liver.
- 2015 Mar;9(2):214-223.
- doi: 10.5009/gnl14095
BACKGROUND/AIMS: Hematological abnormalities during hepatitis C virus (HCV) combination therapy with pegylated interferon alpha and ribavirin often necessitate dose reduction. Variants of the ITPA gene have been reported to protect... -
- CITED
-
- Close
- SHARE
-
- Close
- Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
-
Liu CH, Chen CY, Su WW, Liu CJ, Lo CC, Huang KJ, Chen JJ, Tseng KC, Chang CY, Peng CY, Shih YL, Huang CS, Kao WY, Yang SS, Tsai MC, Wu JH, Chen PY, Su PY, Hwang JJ, Fang YJ, Lee PL, Tseng CW, Lee FJ, Lai HC, Hsieh TY, Chang CC, Chang CH, Huang YJ, Kao JH
- KMID: 2520841
- Clin Mol Hepatol.
- 2021 Oct;27(4):575-588.
- doi: 10.3350/cmh.2021.0155
Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh... -
- CITED
-
- Close
- SHARE
-
- Close
- Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
-
Lu MY, Huang CF, Hung CH, Tai C, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang S, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin C, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML, TACR Study Group
- KMID: 2549384
- Clin Mol Hepatol.
- 2024 Jan;30(1):64-79.
- doi: 10.3350/cmh.2023.0287
Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to... -
- CITED
-
- Close
- SHARE
-
- Close
